Cargando…

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease

Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Huantian, Li, Yuting, Cao, Min, Liao, Jiabao, Liu, Xiangguo, Miao, Jing, Fu, Hui, Song, Ruiwen, Wen, Weibo, Zhang, Zhaiyi, Wang, Hongwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295953/
https://www.ncbi.nlm.nih.gov/pubmed/32581811
http://dx.doi.org/10.3389/fphar.2020.00858
_version_ 1783546744696471552
author Cui, Huantian
Li, Yuting
Cao, Min
Liao, Jiabao
Liu, Xiangguo
Miao, Jing
Fu, Hui
Song, Ruiwen
Wen, Weibo
Zhang, Zhaiyi
Wang, Hongwu
author_facet Cui, Huantian
Li, Yuting
Cao, Min
Liao, Jiabao
Liu, Xiangguo
Miao, Jing
Fu, Hui
Song, Ruiwen
Wen, Weibo
Zhang, Zhaiyi
Wang, Hongwu
author_sort Cui, Huantian
collection PubMed
description Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches.
format Online
Article
Text
id pubmed-7295953
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72959532020-06-23 Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease Cui, Huantian Li, Yuting Cao, Min Liao, Jiabao Liu, Xiangguo Miao, Jing Fu, Hui Song, Ruiwen Wen, Weibo Zhang, Zhaiyi Wang, Hongwu Front Pharmacol Pharmacology Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches. Frontiers Media S.A. 2020-06-09 /pmc/articles/PMC7295953/ /pubmed/32581811 http://dx.doi.org/10.3389/fphar.2020.00858 Text en Copyright © 2020 Cui, Li, Cao, Liao, Liu, Miao, Fu, Song, Wen, Zhang and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cui, Huantian
Li, Yuting
Cao, Min
Liao, Jiabao
Liu, Xiangguo
Miao, Jing
Fu, Hui
Song, Ruiwen
Wen, Weibo
Zhang, Zhaiyi
Wang, Hongwu
Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title_full Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title_fullStr Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title_full_unstemmed Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title_short Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
title_sort untargeted metabolomic analysis of the effects and mechanism of nuciferine treatment on rats with nonalcoholic fatty liver disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295953/
https://www.ncbi.nlm.nih.gov/pubmed/32581811
http://dx.doi.org/10.3389/fphar.2020.00858
work_keys_str_mv AT cuihuantian untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT liyuting untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT caomin untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT liaojiabao untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT liuxiangguo untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT miaojing untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT fuhui untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT songruiwen untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT wenweibo untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT zhangzhaiyi untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease
AT wanghongwu untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease